A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

Source: 
Medical Marketing and Media
snippet: 


The Food and Drug Administration approved CSL Behring’s hemophilia B drug Hemgenix (also known as EtranaDez) last week, the first-ever gene therapy for the disease.

Its one-time cost of $3.5 million set a new benchmark as the highest price for any drug.